Biotechnology

After a dry spell, the city’s biotech scene is showing fresh signs of life as investors pay attention again.

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

The Silicon Valley entrepreneur has turned his body into a living experiment in a bid to reframe longevity as a solvable problem.

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.

Studies are underway to validate the product’s benefits in children who miss elite growth marks but fall outside clinical deficiency.

As competitors flood crowded segments, Dermavon targets skin disorders that others overlook.

With Trump floating tariffs on medicine, suppliers are weighing upgrades, relocation, and, for some, the exit.

From spinning out Takeda’s China assets to acquiring South Korea’s Hugel, CBC is building a global M&A engine with execution at its core.